ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tobevibart

Also written as “VIR-3434” and “Tobevibart”.

Its studies are mostly in Hepatitis B, Chronic · Hepatitis · Fibrosis · Hepatitis D, Chronic, led by 2 companies.

Drug pageTobevibart: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 24, 20259 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vir Biotechnology84 open or runningphase 3since Mar 24, 2025May 25, 2020Dec 2026phase 3 · NCT07128550
Virion Therapeuticsits history only10 open or runningphase 1since Sep 20, 2023Sep 20, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Vir Biotechnology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 25, 2020First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT04423393 · 113 enrolled · Germany, Hong Kong, Korea, Republic of and more
  2. Apr 21, 2021Phase 2 study in Hepatitis B, ChronicNCT04856085 · 244 enrolled · United States, Canada, Germany and more
  3. Jul 1, 2022Phase 2 study in Hepatitis D, ChronicNCT05461170 · 95 enrolled · Bulgaria, France, Germany and more
  4. Jul 15, 2022Phase 1 study in FibrosisNCT05484206 · 88 enrolled · United States
  5. Jul 21, 2022Named tobevibartINNProposed as its International Nonproprietary Name in WHO's List 127 · before, VIR-3434
  6. Nov 3, 2022Phase 2 study in Hepatitis B, ChronicNCT05612581 · 33 enrolled · France, Hong Kong, Moldova and more
  7. Mar 24, 2025Phase 3 study in HepatitisNCT06903338 · 124 enrolled · United States, Canada, Georgia and more
  8. Aug 13, 2025Phase 3 study in HepatitisNCT07128550 · 150 enrolled · Austria, France, Germany and more
  9. Aug 19, 2025Phase 2 study in HepatitisNCT07142811 · 100 enrolled · Belgium, Bulgaria, France and more
  10. Nov 17, 2026Primary completion moved from 2026-11 to 2029-03Date moved laterphase 2 · +28 months · NCT07142811

Ahead

  1. Dec 2026Primary completion: phase 3 study in HepatitisNCT07128550
  2. Mar 2029Primary completion: phase 2 study in HepatitisNCT07142811
  3. Nov 2031Primary completion: phase 2 study in Hepatitis D, ChronicNCT05461170

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 Vir Biotechnology leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07142811Hepatitis · Belgium, Bulgaria, France and more2Active, not recruitingMar 2029100
NCT07128550Hepatitis · Austria, France, Germany and more3Active, not recruitingDec 2026150
NCT06903338Hepatitis · United States, Canada, Georgia and more3Active, not recruitingSep 30, 2026124
NCT05612581Hepatitis B, Chronic · France, Hong Kong, Moldova and more2CompletedOct 15, 202433
NCT05484206Fibrosis · United States1CompletedDec 9, 202588
NCT05461170Hepatitis D, Chronic · Bulgaria, France, Germany and more2Active, not recruitingNov 203195
NCT04856085Hepatitis B, Chronic · United States, Canada, Germany and more2CompletedMar 16, 2026244
NCT04423393Hepatitis B, Chronic · Germany, Hong Kong, Korea, Republic of and more1CompletedOct 24, 2022113

How it is read

Names in the registry

  • “VIR-3434”, 6 entries
  • “Tobevibart”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.